Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
Wang YY, Bai H, Zhang RZ, Yan H, Ning K, Zhao XM · Oncotarget · 2017 September 30
DOI 10.18632/oncotarget.21398
Objective
In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study.
Conclusions
Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach.
Critical Appraisal
Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.
This article has not yet been critically appraised by the Research Hub.
Learn more about Critical Appraisal
